{"meshTags":["Male","Animals","Apoptosis","Mice, Nude","Cell Line","Humans","Xenograft Model Antitumor Assays","Mice","Gene Expression Regulation, Neoplastic","Carcinoma, Non-Small-Cell Lung","Pyrimidines","Receptor, Fibroblast Growth Factor, Type 1","Blotting, Western","Lung Neoplasms","Enzyme Inhibitors","Adenocarcinoma","RNA Interference"],"meshMinor":["Male","Animals","Apoptosis","Mice, Nude","Cell Line","Humans","Xenograft Model Antitumor Assays","Mice","Gene Expression Regulation, Neoplastic","Carcinoma, Non-Small-Cell Lung","Pyrimidines","Receptor, Fibroblast Growth Factor, Type 1","Blotting, Western","Lung Neoplasms","Enzyme Inhibitors","Adenocarcinoma","RNA Interference"],"genes":["FGFR1 gene-which","fibroblast growth factor receptor 1"],"publicationTypes":["Comment","Journal Article"],"abstract":"A report in this issue of Science Translational Medicine reveals that amplification of the FGFR1 gene-which encodes fibroblast growth factor receptor 1-is a major oncogenic aberration in squamous cell lung cancer. This genetic variation may represent the first relatively high-frequency therapeutic target of smoking-associated lung cancer.","title":"A therapeutic target for smoking-associated lung cancer.","pubmedId":"21160076"}